Navigation Links
BioMed Realty Trust Announces Planned Filing of Resale Registration Statement in Connection With 3.75% Exchangeable Senior Notes Due 2030
Date:6/14/2010

SAN DIEGO, June 14 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that, in connection with its January 2010 offering of $180.0 million aggregate principal amount of 3.75% Exchangeable Senior Notes due 2030 (inclusive of a $30.0 million over-allotment option) by its operating partnership, BioMed Realty, L.P., BioMed Realty Trust intends to file with the Securities and Exchange Commission, on or around July 8, 2010, a resale registration statement on Form S-3 to cover the resales of BioMed Realty Trust common stock that may be issued from time to time upon exchange of the notes.  The resale registration statement is anticipated to be immediately effective upon filing. 

Holders of the notes who wish to be named in the prospectus to be contained in the resale registration statement in order to sell the common stock issuable to them upon exchange of their notes should complete a selling stockholder notice and questionnaire contained in the offering memorandum for the notes and return it, no later than June 28, 2010, to: BioMed Realty Trust, Inc., 17190 Bernardo Center Drive, San Diego, CA 92128, Attention: General Counsel.

This release is being issued in order to comply with the terms of the indenture and registration rights agreement relating to the notes.  This release shall not constitute an offer to sell or the solicitation of an offer to buy any of BioMed Realty Trust's or its operating partnership's securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.  

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially.  These risks and uncertainties include, without limitation: the company's ability to file and cause to become effective a registration statement relating to the notes, general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions and developments, and the ability to refinance indebtedness as it comes due; failure to maintain the company's investment grade credit ratings with the rating agencies; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q.  The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioMed Realty Trust Promotes Greg Lubushkin to Chief Financial Officer
2. BioMed Realty Trust Breaks Ground on 176,000 Square Foot R&D Facility for Isis Pharmaceuticals in Carlsbad, California
3. Biomedical Structures Receives Growth Capital from Ampersand Ventures to Fund Ongoing Expansion
4. BioMed Realty Trust to Webcast Company Presentation at Investor Day 2010
5. BioMed Realty, L.P. Prices Private Offering of $250 Million of 6.125% Senior Unsecured Notes Due 2020
6. BioMed Realty Trust Declares First Quarter 2010 Common Stock and Preferred Stock Dividends
7. Outreach Program to Increase Awareness of New Advances in Biomedical Research to Treat Down Syndrome Cognitive Impairment
8. BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts
9. NIH Director Francis Collins to Speak at National Press Club February 26 on A New Era of Quantum Leaps in Biomedical Research
10. Biomedical Industry Jobs Critical to Californias Economic Recovery, Finds California Healthcare Institute and PricewaterhouseCoopers
11. BioMed Realty Trust to Report 2009 Fourth Quarter and Year-End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 2016  Regenicin, Inc. (OTC Bulletin Board: ... development and commercialization of regenerative cell therapies to ... recently reported the Company,s operating results for 2015 ... Lonza America , Inc. (the "Lonza ... in the process of consummating an agreement to ...
(Date:2/9/2016)... ... 09, 2016 , ... The American Academy of Thermology (AAT) has ... 2016 AAT Member Certification Qualification Course for Technicians via a two part webinar on ... include a detailed review of hardware, software, and camera setup/operations, aligns with the in-person ...
(Date:2/9/2016)... and LONDON , February 9, 2016 /PRNewswire/ ... tech replace paper and protect IP   ... laboratory notebook (ELN) will be rolled out in ... and development (R&D) and protect valuable IP. Users will be ... a specific researcher or experiment as part of the application, ...
(Date:2/8/2016)... 8, 2016 Should antibiotic bone cement products ... to prevent infection after standard total hip or knee ... ECRI Institute have been fielding a lot lately. ... Bottom Line?" --> "Antibiotic Bone ... --> While there isn,t a simple ...
Breaking Biology Technology:
(Date:1/13/2016)... New York , January 13, 2016 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2023. According to the ... in 2014 and is anticipated to reach US$1,625.8 mn ... 2015 to 2023. In terms of volume, the biometric ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
(Date:1/8/2016)... and MANCHESTER, United Kingdom , Jan. 8, ... of innovative sensor-based diagnostic products, today announced the closing of ... and existing investors.  Proceeds from the financing will be used ... a hand-held device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction ...
Breaking Biology News(10 mins):